drugset / Trial / NCT01232712
A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The scientific approach behind this study is to develop novel anti-cancer therapeutic vaccine to induce a robust cellular immune response mediated via both CD4+ and CD8+ T lymphocytes populations and can be be applicable to the majority of the target population.
Timeline
- Start
- 2010-09
- Primary completion
- 2013-05
- Completion
- 2013-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ImMucin | Peptide | 100 ug | Subcutaneous |
| Subject | ImMucin | Peptide | 250 ug | Subcutaneous |
| Background | hGM-CSF | Protein / enzyme biologic | 250 ug | — |